Meeting NewsVideo

BTK inhibitors provide ‘exciting time’ for the treatment of lymphoma subtype

February 10, 2018
ATLANTA — Three studies evaluating the use of different Bruton’s tyrosine kinase inhibitors presented at the ASH Annual Meeting and…
Meeting News

Study results may lead to ‘completely different way’ of treating lymphoma subtype

February 9, 2018
ATLANTA — Results from the updated ZUMA-1 trial indicate that CAR T-cell therapies are effective for various cancers that have not yet received…
Meeting News

Better targeted therapies likely coming for lymphoma subtype

February 5, 2018
ATLANTA — Advances in the treatment of mantle cell lymphoma comprised several studies presented at the ASH Annual Meeting and Exposition. …
Meeting News

Rituximab maintenance demonstrates survival benefit after chemotherapy in lymphoma subtype

January 25, 2018
ATLANTA — Rituximab maintenance after rituximab plus CHOP chemotherapy demonstrated significantly prolonged PFS and OS in first-line treatment…
Meeting News

Brentuximab vedotin shows promise in Hodgkin lymphoma, concerns remain

January 24, 2018
ATLANTA — Brentuximab vedotin reduced the number of patients with Hodgkin lymphoma who required subsequent treatment, according to results of…
Meeting News

Ibrutinib, nivolumab combination may provide new option in non-Hodgkin lymphoma subtypes

January 22, 2018
ATLANTA — Combination therapy with ibrutinib and nivolumab appears safe and effective for several subtypes of relapsed, refractory non-Hodgkin…
Meeting NewsPerspective

Active surveillance shows benefit for rare Hodgkin lymphoma subtype

January 10, 2018
ATLANTA — Active surveillance appeared to be a feasible strategy for the management of nodular lymphocyte-predominant Hodgkin lymphoma…
Meeting NewsVideo

VIDEO: Studies may lead to ‘era’ where chemotherapy is not needed for lymphoma subtype

December 15, 2017
ATLANTA — Two long-term follow-up studies presented at the ASH Annual Meeting and Exposition may indicate a future where patients with mantle…